Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 7/20 | 0.40 |
| ▸ | ABAT | P80404 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | F11 | P03951 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.33 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.31 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7431850 | 0.75 | — | — | |
| SCHEMBL1197678 | 0.73 | — | — | |
| SCHEMBL61322 | 0.73 | — | — | |
| SCHEMBL1304221 | 0.73 | — | — | |
| SCHEMBL2170353 | 0.73 | — | — | |
| SCHEMBL3924093 | 0.69 | TAAR1 (0.41) | LOXL2TAAR1CA1CA2CA12 | |
| SCHEMBL15828 | 0.67 | HRH3 (0.79) | HRH3LOXL2ABATTAAR1CA1 | |
| SCHEMBL28838458 | 0.67 | TPSAB1 (0.37) | HRH3LOXL2ABATCA1CA2 | |
| SCHEMBL1404345 | 0.67 | LPL (0.39) | CA2 | |
| SCHEMBL21373792 | 0.65 | TAAR1 (0.37) | TAAR1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104744434-A | ISOINDOLINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | CELGENE CORP | 2015-07-01 | — | — | CN | claimed |
| CN-102264720-A | Isoindoline compounds for the treatment of cancer | — | 2011-11-30 | — | — | CN | claimed |
| EP-1603562-A4 | SULFONYL-AMIDINO CONTAINING AND TETRAHYDROPYRIMIDINO CONTAINING COMPOUNDS AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-10-22 | — | — | EP | claimed |
| EP-1603909-A4 | LINEAR CHAIN SUBSTITUTED MONOCYCLIC AND BICYCLIC DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-09-03 | — | — | EP | claimed |
| US-7312214-B2 | 1, 1-disubstituted cycloalkyl derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-25 | — | — | US | claimed |
| US-7135469-B2 | Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors | BRISTOL MYERS SQUIBB, CO. (US) | 2006-11-14 | — | — | US | claimed |
| EP-1505966-A4 | 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2006-08-30 | — | — | EP | claimed |
| EP-1603909-A2 | LINEAR CHAIN SUBSTITUTED MONOCYCLIC AND BICYCLIC DERIVATIVES AS FACTOR XA INHIBITORS | Brystol-Myers Squibb Company (US) | 2005-12-14 | — | — | EP | claimed |
| EP-1603562-A2 | SULFONYL-AMIDINO CONTAINING AND TETRAHYDROPYRIMIDINO CONTAINING COMPOUNDS AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-12-14 | — | — | EP | claimed |
| EP-1505966-A1 | 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-02-16 | — | — | EP | claimed |
| US-20040254158-A1 | Anticoagulants; atherosclerosis; strokes; thrombosis; cardiovascular disorders | BRISTOL-MYERS SQUIBB COMPANY | 2004-12-16 | — | — | US | claimed |
| US-20040214808-A1 | Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-28 | — | — | US | claimed |
| US-20040209863-A1 | Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-21 | — | — | US | claimed |
| WO-2004083177-A2 | LINEAR CHAIN SUBSTITUTED MONOCYCLIC AND BICYCLIC DERIVATIVES AS FACTOR XA INHIBITORS | BRYSTOL-MYERS SQUIBB COMPANY (US) | 2004-09-30 | — | — | WO | claimed |
| WO-2004083174-A2 | SULFONYL-AMIDINO CONTAINING AND TETRAHYDROPYRIMIDINO CONTAINING COMPOUNDS AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-09-30 | — | — | WO | claimed |
| WO-2003099276-A1 | 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-04 | — | — | WO | claimed |
| CN-110352213-A | Film | 住友化学株式会社 | 2019-10-18 | — | — | CN | disclosed |
| CN-105358177-B | Combination therapy comprising TOR kinase inhibitor and IMID compound for treating cancer | 西格诺药品有限公司 | 2018-11-23 | — | — | CN | disclosed |
| US-6602871-B2 | Anticoagulants; compounds of given formula: several types of nitrogen containing heterocycles such as perhydroindolizine, piperazine, pyrimidine | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-08-05 | — | — | US | disclosed |
| US-20020115854-A1 | Thrombin or factor Xa inhibitors | LAM PATRICK Y S (US) | 2002-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214808-A1 | Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors | TFPI, F12, F2 | HRH3 2494/4885LOXL2 1523/4885ABAT 2767/4885 |
| US-20040254158-A1 | Anticoagulants; atherosclerosis; strokes; thrombosis; cardiovascular disorders | SERPINC1, PCSK9, PLAT | HRH3 3654/4885LOXL2 320/4885ABAT 559/4885 |
| US-20040209863-A1 | Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors | TFPI, SPINT2, TMPRSS4 | HRH3 2019/4885LOXL2 3639/4885ABAT 3020/4885 |
| US-20020115854-A1 | Thrombin or factor Xa inhibitors | SERPINC1, TFPI, SPINT2 | HRH3 2094/4885LOXL2 1231/4885ABAT 2753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.